Terns Pharmaceuticals (TERN) Price & Analysis

Compare

528 Followers

TERN Stock Chart & Stats

$47.78

-$0.29(-5.06%)

At close: Jan 08 4:00 PM EST

$47.78

-$0.29(-5.06%)

Day’s Range― - ―

52-Week Range$1.87 - $48.26

Previous CloseN/A

Volume294.76K

Average Volume (3M)2.00M

Market Cap

$5.08B

Enterprise Value$4.15B

Total Cash (Recent Filing)$295.63M

Total Debt (Recent Filing)$1.03M

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Mar 31, 2026

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding106,329,780

10 Day Avg. Volume2,167,431

30 Day Avg. Volume1,996,631

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)1.27

Price to Sales (P/S)0.00

P/FCF Ratio-6.29

Enterprise Value/Market Cap0.82

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-38.47K

Enterprise Value/Ebitda-40.93

Forecast

1Y Price Target

$55.60

Price Target Upside16.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.18

Revenue Forecast (FY)$1.07M

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyAnalyst notes that early CARDINAL trial results show substantially higher and durable molecular response rates versus comparators, supporting potential to outperform current chronic myeloid leukemia treatments.

Development Progress And FinancingManagement plans staggered pivotal trials in frontline and later-line disease while the company maintains a strong cash runway that materially de-risks continued clinical advancement.

Safety And Patient ConvenienceEarly data indicate a clean safety profile with no observed pancreatic, hypertension, or cardiovascular toxicity and once-daily dosing without food restrictions, which may drive clinician and patient preference.

Bears Say

Analyst Coverage And Valuation VisibilityAnalyst's price target remains unavailable, creating limited valuation transparency and increasing uncertainty for investors assessing the stock's upside.

Market Penetration And Commercial RiskConfidence in winning frontline use is critical given current valuation, so failure to secure broad adoption against established therapies would represent a major downside risk.

Regulatory Risk And TimingUnresolved key regulatory interactions and an outstanding end-of-phase-2 meeting introduce uncertainty that could delay initiation or design of pivotal trials and slow clinical progress.

Terns Pharmaceuticals News

Terns Parmaceuticles options imply 11.1% move in share price post-earnings

Pre-earnings options volume in Terns Parmaceuticles is 1.5x normal with calls leading puts 9:7. Implied volatility suggests the...

12h ago

TERN

Unusually active option classes on open March 13th

Unusual total active option classes on open include: Terns Parmaceuticles (TERN), Himax (HIMX), New Era Energy & Digital...

7d ago

MOS

Reaffirming Buy on Terns Pharmaceuticals: Strong Early TERN-701 Data Drive Upgraded Long-Term Revenue Outlook and Upside Potential

TD Cowen analyst Yaron Werber has maintained their bullish stance on TERN stock, giving a Buy rating on...

29d ago

TERN

Terns Pharmaceuticals initiated with an Outperform at Leerink

Leerink initiated coverage of Terns Pharmaceuticals (TERN) with an Outperform rating and $58 price target Terns is a...

1M ago

TERN

Terns Pharmaceuticals Expands Global Rights to TERN-701

Terns Pharmaceuticals ( ($TERN) ) has provided an update. On January 16, 2026, Terns Pharmaceuticals amended its existing...

2M ago

TERN

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

Shares of several names in the obesity-drug space, including Viking Therapeutics (VKTX), Terns Pharmaceuticals (TERN), and Structure Therapeutics...

2M ago

LLY

NVO

Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports

Novo Nordisk (NVO) is back on the hunt for deals to boost its obesity portfolio after losing U.S....

2M ago

LLY

NVO

De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals

BMO Capital analyst Evan Seigerman has maintained their bullish stance on TERN stock, giving a Buy rating today....

2M ago

TERN

TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals

William Blair analyst Andy Hsieh has reiterated their bullish stance on TERN stock, giving a Buy rating on...

2M ago

TERN

5 Stocks That Moved the Most in 2025 – What Lies Ahead

The year 2025 has been anything but quiet, and a handful of mid‑ and large‑cap names have delivered...

3M ago

RGC

ABVX

Terns Pharmaceuticals Announces Major Stock Offering

Terns Pharmaceuticals ( ($TERN) ) just unveiled an update. On December 9, 2025, Terns Pharmaceuticals announced an underwritten...

3M ago

TERN

Terns Pharmaceuticals price target raised to $57 from $35 at Citizens

Citizens raised the firm’s price target on Terns Pharmaceuticals (TERN) to $57 from $35 and keeps an Outperform...

3M ago

TERN

Midday Fly By: SK Hynix weighs U.S. listing, GE Vernova doubles dividend

The major averages were mixed near noon as investors await the conclusion of the Federal Reserve’s policy meeting,...

3M ago

Terns Pharmaceuticals 16.25M share Secondary priced at $40.00

The deal size was increased to $502M in common stock from $400M in common stock. Jefferies, TD Cowen...

3M ago

TERN

TERN FAQ

What was Terns Pharmaceuticals’s price range in the past 12 months?

Terns Pharmaceuticals lowest stock price was $1.86 and its highest was $48.26 in the past 12 months.

What is Terns Pharmaceuticals’s market cap?

Terns Pharmaceuticals’s market cap is $5.08B.

When is Terns Pharmaceuticals’s upcoming earnings report date?

Terns Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 11 days.

How were Terns Pharmaceuticals’s earnings last quarter?

Terns Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.024.

Is Terns Pharmaceuticals overvalued?

According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Terns Pharmaceuticals pay dividends?

Terns Pharmaceuticals does not currently pay dividends.

What is Terns Pharmaceuticals’s EPS estimate?

Terns Pharmaceuticals’s EPS estimate is -0.29.

How many shares outstanding does Terns Pharmaceuticals have?

Terns Pharmaceuticals has 106,329,780 shares outstanding.

What happened to Terns Pharmaceuticals’s price movement after its last earnings report?

Terns Pharmaceuticals reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went up 7.636%.

Which hedge fund is a major shareholder of Terns Pharmaceuticals?

Currently, no hedge funds are holding shares in TERN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Terns Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-29.95%

Trailing 12-Months

Asset Growth

-20.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Terns Pharmaceuticals

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals (TERN) Earnings & Revenues

Historic Earnings Reports

TERN Stock 12 Month Forecast

Average Price Target

$55.60

▲(16.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","30":"$30","59":"$59","15.5":"$15.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,15.5,30,44.5,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.82,38.449230769230766,40.07846153846154,41.707692307692305,43.33692307692308,44.966153846153844,46.59538461538462,48.22461538461538,49.853846153846156,51.48307692307692,53.112307692307695,54.74153846153846,56.37076923076923,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.82,38.26461538461538,39.70923076923077,41.15384615384615,42.598461538461535,44.043076923076924,45.487692307692306,46.93230769230769,48.37692307692308,49.821538461538466,51.26615384615385,52.71076923076923,54.15538461538462,{"y":55.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.82,38.14153846153846,39.463076923076926,40.784615384615385,42.106153846153845,43.42769230769231,44.74923076923077,46.07076923076923,47.392307692307696,48.713846153846156,50.035384615384615,51.35692307692308,52.67846153846154,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >